NXTCL Stock Overview
A biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NextCell Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.76 |
| 52 Week High | SEK 4.03 |
| 52 Week Low | SEK 1.16 |
| Beta | 0.71 |
| 11 Month Change | -10.66% |
| 3 Month Change | 35.38% |
| 1 Year Change | -42.86% |
| 33 Year Change | -78.48% |
| 5 Year Change | -62.95% |
| Change since IPO | -47.46% |
Recent News & Updates
Recent updates
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Mar 09
We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate
Oct 07NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
May 23NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
Feb 01We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth
Sep 21Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation
May 31We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Feb 15Shareholder Returns
| NXTCL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.2% | -5.8% | -2.1% |
| 1Y | -42.9% | 14.3% | 10.8% |
Return vs Industry: NXTCL underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: NXTCL underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| NXTCL volatility | |
|---|---|
| NXTCL Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: NXTCL's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: NXTCL's weekly volatility has decreased from 21% to 9% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 24 | Mathias Svahn | www.nextcellpharma.com |
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank.
NextCell Pharma AB Fundamentals Summary
| NXTCL fundamental statistics | |
|---|---|
| Market cap | SEK 126.45m |
| Earnings (TTM) | -SEK 41.96m |
| Revenue (TTM) | SEK 11.28m |
11.4x
P/S Ratio-3.1x
P/E RatioIs NXTCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTCL income statement (TTM) | |
|---|---|
| Revenue | SEK 11.28m |
| Cost of Revenue | SEK 15.22m |
| Gross Profit | -SEK 3.94m |
| Other Expenses | SEK 38.02m |
| Earnings | -SEK 41.96m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | -0.57 |
| Gross Margin | -34.97% |
| Net Profit Margin | -372.04% |
| Debt/Equity Ratio | 0% |
How did NXTCL perform over the long term?
See historical performance and comparison